A drug-discovery company focused on oncology
Oxford, England
Joined January 2017
- Tweets717
- Following217
- Followers718
- Likes199
@OxDrugDes is delighted to announce the latest member to join our Scientific Advisory Board, oncologist Professor Sarah Blagden!
oxforddrugdesign.com/index.p…
@OxDrugDes announces the successful in vivo validation of our novel oncology therapeutic mechanism targeting multiple tumours. The validation was confirmed through a 28-day mouse trial that demonstrated both clear efficacy and dose response.
oxforddrugdesign.com/index.p…
@OxDrugDes initiates its collaborative research by applying their pioneering AI platform to accelerate oncology drug discovery at @PhoreMostLtd
oxforddrugdesign.com/2023/03…
@OxDrugDes announces the successful completion of its initial proof-of-concept studies towards a novel therapeutic approach against cancer. #anticancer #aiforhealth
@OxDrugDes welcomes Dr Richard Cooper of @UniofOxford as Head of Machine Learning and Prof. Xiang-Lei Yang of @scrippsresearch to its Scientific Advisory Board. #anticancer #aiforhealth
oxforddrugdesign.com/2022/09…
@OxDrugDes appoints Dr Richard Cooper as Head of Machine Learning and Prof. Xiang-Lei Yang to its Scientific Advisory Board. #anticancer #aiforhealth
oxforddrugdesign.com/2022/09…
2
@OxDrugDes has been selected to present at this year's RESI Boston investor conference, Sept 21-23. Excited to pitch to a live audience and connect with investors on our ground-breaking advances in anti-cancer therapies! #anticancer #aiforhealth #venturecapital #drugdiscovery
Like millions of her fans worldwide, we deeply regret the passing of Olivia Newton John. Not only a wonderful artist and granddaughter of the great physicist Max Born but a huge supporter of cancer research. bbc.co.uk/news/health-624798…
1
5
This is an area of our own work and where we now have promising novel future treatments.
#breastcancer #anticancer #therapeutics #aiforhealth #oxforduniversity
Our CSO Paul Finn is taking part in a panel for emerging opportunities in tRNA therapeutics at the 28th tRNA Conference today at 4:45pm EST. Find out more about our work targeting tRNA synthetases for #antimicrobialresistance and #oncology!
oxforddrugdesign.com/2022/06…
3
Paul Finn, CSO, is attending the 28th tRNA Conference this week! Find us or get in contact if you would like to know more about the work we are doing!
Catch our CSO Paul Finn discussing our work discovering potent Gram-negative antibacterials targeting leucyl-tRNA synthetase at #ASMicrobe on Saturday 11 June at 14:15 EDT
oxforddrugdesign.com/2022/06…
1
ODD is #hiring a computational chemist.
Find out more about this exciting opportunity...
oxforddrugdesign.com/job_des…
We are pleased to announce $2.7 (£2.2) million in bridge round funding commitments received from our existing investors o2h Ventures, ACF Investors, Jonathan Milner, US-based R42 Group, returning angels and new investors.
oxforddrugdesign.com/2022/05…
5
ODD is #hiring a Director of #businessdevelopment.
Find out more about this exciting opportunity...
linkedin.com/jobs/view/29979…
ODD are #hiring a Director of #businessdevelopment.
Find out more in this article...
linkedin.com/feed/update/urn…
1
ODD chairman, Graham Richards, joins entrepreneur and tech investor @robinklein on this month's episode of the #2020visionpod linktr.ee/2020VisionWithRobi…
2
Oxford Drug Design retweeted
Delighted to launch the latest episode of the 20:20 Vision podcast. My conversation with Prof.Graham Richards goes in multiple directions exploring how he came to be the significant scientist he became.2020vision.libsyn.com/websit…
